Monthly Archives: March 2019

Enforcement Updates: OPDP Issues First Letter of the Year

In recent years, FDA’s Office of Prescription Drug Promotion (OPDP) has been diminished in the volume of its enforcement expressed through the issuance of Warning and Untitled Letters. OPDP now sends out only a handful of letters each year when … Continue reading

Posted in Warning Letters | Tagged , , | 2 Comments

Gottlieb Set a New Bar – What Happens Now?

The news that Dr. Gottlieb was leaving his post as Commissioner of FDA took everyone by surprise. Perhaps another surprise to many was the skill and judgment he brought to the job when initially he faced many critics due to … Continue reading

Posted in Current Affairs, FDA Image | Tagged , , | Comments Off on Gottlieb Set a New Bar – What Happens Now?

In the Pharma Pricing Debate, We Are Talking About More Than Apples and Oranges

This week the Senate Finance Committee held the second in what will be four hearings on the price of pharmaceutical drugs – Drug Pricing in America: A Prescription for Change. The first hearing, on January 29, listened to a panel … Continue reading

Posted in Pharma Industry Image, Pricing and Value | Comments Off on In the Pharma Pricing Debate, We Are Talking About More Than Apples and Oranges